Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023 16:01 ET | Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023 16:05 ET | Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023 09:01 ET | Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 1, 2023, the...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
September 25, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
August 30, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
August 10, 2023 16:05 ET | Vor Biopharma
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs ...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
August 01, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...